Advertisement

European Journal of Clinical Pharmacology

, Volume 69, Issue 2, pp 245–253 | Cite as

Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors’ adherence to warfarin therapy recommendations

A Swedish study of prescribed drugs in primary care in 2002 and 2007
  • Axel C. CarlssonEmail author
  • Per Wändell
  • Kristina Sundquist
  • Sven-Erik Johansson
  • Jan Sundquist
Pharmacoepidemiology and Prescription

Abstract

Background

Little is known about prescription trends in atrial fibrillation (AF) in primary health care in Sweden.

Objective

The aim was to study time trends in pharmacotherapy, in men and women with AF. We also aimed at studying doctors’ adherence to CHADS2 for prescribing warfarin. CHADS2 assesses stroke risk by presence of known risk factors, i.e., congestive heart failure, hypertension, age >75 years, diabetes, previous stroke and transient ischemic attack.

Methods

Data were obtained from primary health care records that contained individual clinical data. In total, 371,036 patients were included in the sample from 2002, and 424,329 patients were included in the sample from 2007. The study population consisted of individuals aged 45+ years who were diagnosed with AF in 2002 (1,330 men and 1,096 women) and 2007 (2,748 men and 2,234 women). The pharmacotherapies prescribed in 2002 and 2007 were analyzed separately in men and women. Logistic regression was used to calculate the association between the CHADS2 score and prescribed warfarin treatment.

Results

Selective beta-blockers, anti-coagulant therapy and lipid-lowering drugs were prescribed more frequently in 2007 than in 2002. In 2007, antithrombotic and RAS-blocking agents were prescribed more frequently to men, whereas beta-1 selective beta-blockers were prescribed more frequently to women. There was no consistent association between the CHADS2 score and prescribed warfarin treatment.

Conclusions

Pharmacotherapy of AF has improved over time, though CHADS2 guidelines need to be implemented systematically in primary health care in Sweden to decrease the risk of stroke and improve quality of life in patients with AF.

Keywords

Atrial fibrillation Pharmacotherapy Gender Warfarin CHADS2 Sweden 

Notes

Acknowledgments

This work was supported by grants to Kristina Sundquist and Jan Sundquist from the Swedish Research Council (K2005-27X-15428-01A, 2008-3110 and 2008-2638), the Swedish Council for Working Life and Social Research (2006-0386, 2007-1754 and 2007-1962) and the Swedish Research Council Formas (2006-4255-6596-99 and 2007-1352).

References

  1. 1.
    Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD (2010) Gender in atrial fibrillation: ten years later. Gend Med 7(3):206–217. doi: 10.1016/j.genm.2010.06.001 PubMedCrossRefGoogle Scholar
  2. 2.
    Wandell PE (2001) A survey of subjects with present or previous atrial fibrillation in a Swedish community. Scand J Prim Health Care 19(1):20–24PubMedGoogle Scholar
  3. 3.
    Volgman AS, Manankil MF, Mookherjee D, Trohman RG (2009) Women with atrial fibrillation: greater risk, less attention. Gend Med 6(3):419–432. doi: 10.1016/j.genm.2009.09.008 PubMedCrossRefGoogle Scholar
  4. 4.
    Naccarelli GV, Varker H, Lin J, Schulman KL (2009) Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 104(11):1534–1539. doi: 10.1016/j.amjcard.2009.07.022 PubMedCrossRefGoogle Scholar
  5. 5.
    Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB (2004) Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 94(7):889–894. doi: 10.1016/j.amjcard.2004.06.023 PubMedCrossRefGoogle Scholar
  6. 6.
    van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE (2009) Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 40(4):1410–1416. doi: 10.1161/STROKEAHA.108.526988 PubMedCrossRefGoogle Scholar
  7. 7.
    van Walraven C, Hart RG, Singer DE, Koudstaal PJ, Connolly S (2003) Oral anticoagulants vs. aspirin for stroke prevention in patients with non-valvular atrial fibrillation: the verdict is in. Card Electrophysiol Rev 7(4):374–378. doi: 10.1023/B:CEPR.0000023143.98705.ee PubMedCrossRefGoogle Scholar
  8. 8.
    van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B (2002) Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288(19):2441–2448PubMedCrossRefGoogle Scholar
  9. 9.
    Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE (2008) Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 51(8):810–815. doi: 10.1016/j.jacc.2007.09.065 PubMedCrossRefGoogle Scholar
  10. 10.
    Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE (1999) Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 131(12):927–934PubMedGoogle Scholar
  11. 11.
    Go AS, Hylek EM, Phillips KA, Borowsky LH, Henault LE, Chang Y, Selby JV, Singer DE (2000) Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 102(1):11–13PubMedCrossRefGoogle Scholar
  12. 12.
    Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS (2009) The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 151(5):297–305PubMedGoogle Scholar
  13. 13.
    Henriksson KM, Farahmand B, Johansson S, Asberg S, Terent A, Edvardsson N (2010) Survival after stroke–the impact of CHADS2 score and atrial fibrillation. Int J Cardiol 141(1):18–23. doi: 10.1016/j.ijcard.2008.11.122 PubMedCrossRefGoogle Scholar
  14. 14.
    Wandell PE (1999) Drug use in patients with atrial fibrillation in Swedish primary health care: a comparison 5 years apart. Eur J Clin Pharmacol 55(4):333–337PubMedCrossRefGoogle Scholar
  15. 15.
    Hemminki K, Li X, Sundquist K (2007) Familial risks for nerve, nerve root and plexus disorders in siblings based on hospitalisations in Sweden. J Epidemiol Community Health 61(1):80–84. doi: 10.1136/jech.2006.046615 PubMedCrossRefGoogle Scholar
  16. 16.
    Li X, Sundquist J, Sundquist K (2008) Socioeconomic and occupational risk factors for rheumatoid arthritis: a nationwide study based on hospitalizations in Sweden. J Rheumatol 35(6):986–991PubMedGoogle Scholar
  17. 17.
    Sundquist K, Li X (2006) Coronary heart disease risks in first- and second-generation immigrants in Sweden: a follow-up study. J Intern Med 259(4):418–427. doi: 10.1111/j.1365-2796.2006.01630.x PubMedCrossRefGoogle Scholar
  18. 18.
    Wandell PE, Carlsson AC, Sundquist K, Johansson SE, Sundquist J (2011) Total mortality among levothyroxine-treated women with atrial fibrillation in Swedish primary health care. Int J Cardiol 152(1):147–148. doi: 10.1016/j.ijcard.2011.07.066 PubMedCrossRefGoogle Scholar
  19. 19.
    Carlsson AC, Wandell PE, Journath G, de Faire U, Hellenius ML (2009) Factors associated with uncontrolled hypertension and cardiovascular risk in hypertensive 60-year-old men and women–a population-based study. Hypertens Res 32(9):780–785. doi: 10.1038/hr.2009.94 PubMedCrossRefGoogle Scholar
  20. 20.
    Journath G, Hellenius ML, Carlsson AC, Wandell PE, Nilsson PM (2010) Physicians' gender is associated with risk factor control in patients on antihypertensive and lipid lowering treatment. Blood Press 19(4):240–248. doi: 10.3109/08037051003768247 PubMedCrossRefGoogle Scholar
  21. 21.
    Pimenta E, Stowasser M (2009) Uncontrolled hypertension: beyond pharmacological treatment. Hypertens Res 32(9):729–731. doi: 10.1038/hr.2009.108 PubMedCrossRefGoogle Scholar
  22. 22.
    Glader EL, Sjolander M, Eriksson M, Lundberg M (2010) Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 41(2):397–401. doi: 10.1161/STROKEAHA.109.566950 PubMedCrossRefGoogle Scholar
  23. 23.
    Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, Sheldon R, Talajic M, Dorian P, Newman D (2001) New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 103(19):2365–2370PubMedCrossRefGoogle Scholar
  24. 24.
    Bajpai A, Savelieva I, Camm AJ (2008) Treatment of atrial fibrillation. Br Med Bull 88(1):75–94. doi: 10.1093/bmb/ldn046 PubMedCrossRefGoogle Scholar
  25. 25.
    Chan JD, Rea TD, Smith NL, Siscovick D, Heckbert SR, Lumley T, Chaves P, Furberg CD, Kuller L, Psaty BM (2005) Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS). Am Heart J 150(3):464–470. doi: 10.1016/j.ahj.2004.12.022 PubMedCrossRefGoogle Scholar
  26. 26.
    Glazer NL, Dublin S, Smith NL, French B, Jackson LA, Hrachovec JB, Siscovick DS, Psaty BM, Heckbert SR (2007) Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med 167(3):246–252. doi: 10.1001/archinte.167.3.246 PubMedCrossRefGoogle Scholar
  27. 27.
    Wandell PE (2001) Anticoagulant treatment of patients in Swedish primary health care. Safety aspects. Eur J Clin Pharmacol 57(1):61–64PubMedCrossRefGoogle Scholar
  28. 28.
    Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS (2005) Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 112(12):1687–1691. doi: 10.1161/CIRCULATIONAHA.105.553438 PubMedCrossRefGoogle Scholar
  29. 29.
    Lip GY, Frison L, Halperin JL, Lane DA (2010) Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 41(12):2731–2738. doi: 10.1161/STROKEAHA.110.590257 PubMedCrossRefGoogle Scholar
  30. 30.
    Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2):263–272. doi: 10.1378/chest.09-1584 PubMedCrossRefGoogle Scholar
  31. 31.
    Sundquist K, Chaikiat A, Leon VR, Johansson SE, Sundquist J (2011) Country of birth, socioeconomic factors, and risk factor control in patients with type 2 diabetes: a Swedish study from 25 primary health-care centres. Diabetes Metab Res Rev 27(3):244–254. doi: 10.1002/dmrr.1161 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Axel C. Carlsson
    • 1
    • 2
    • 5
    Email author
  • Per Wändell
    • 1
  • Kristina Sundquist
    • 3
  • Sven-Erik Johansson
    • 3
  • Jan Sundquist
    • 3
    • 4
  1. 1.Center for Family and Community MedicineKarolinska InstitutetStockholmSweden
  2. 2.Department of Public Health and Caring Sciences/ Section of GeriatricsUppsala UniversityUppsalaSweden
  3. 3.Center for Primary Health Care ResearchLund UniversityMalmöSweden
  4. 4.Stanford Prevention Research CenterStanford University School of MedicinePalo AltoUSA
  5. 5.Center for Family and Community MedicineKarolinska InstitutetHuddingeSweden

Personalised recommendations